(PRWEB) November 16, 2016
On November 11, 2016, RegenLab USA LLC filed a patent infringement lawsuit for equitable relief and monetary damages in the U.S. District Court for the Southern District of New York against Estar Technologies Ltd., Eclipse Aesthetics LLC, and Healeon Medical, Inc. (Case 1:16-cv-08771).
RegenLab, whose products are marketed under the renowned REGENLAB® brand, is a leading developer of medical products for the preparation of platelet rich plasma. Platelet rich plasma contains a high concentration of blood platelets and proteins that promote natural wound healing for indicated uses. RegenLab developed a new and extremely effective way to enhance platelet rich plasma production, which is patented in U.S. Pat. No. 8,529,957 (“the ‘957 patent”).
RegenLab has alleged within court documents that Estar, Eclipse, and Healeon have manufactured, imported, and sold products marketed under the brands Eclipse PRP and Healeon PRP, which infringe the ‘957 patent. RegenLab is pursuing a permanent injunction to prevent these companies from actively inducing their customers to use these products, which use itself violates RegenLab’s patent. RegenLab also seeks past damages resulting from the use of the infringing products by defendants and their customers.
From 2011 until 2013, Eclipse was a distributor of RegenLab’s products. RegenLab terminated the distribution agreement in 2013, immediately after receiving a letter from the FDA that Eclipse was violating its regulations in the use and marketing of RegenLab’s products. Shortly after RegenLab severed their relationship, Eclipse began selling and marketing “Eclipse PRP”, which RegenLab alleges is a copy of its own products. Similarly, Healeon sells “Healeon PRP,” which RegenLab alleges is a relabeled Eclipse PRP product. Estar manufactures both the Eclipse PRP and Healeon PRP products.
Concurrent with the United States patent infringement action, RegenLab’s affiliate in Switzerland, Regen Lab SA, filed a patent infringement lawsuit against Estar Medical Ltd. in Dusseldorf District Court in Germany (Case 4b O 117/16). That lawsuit alleges Estar has infringed European patent EP2073862 B1, which is related to the ‘957 patent.
RegenLab is a recognized, highly-acclaimed innovator. RegenLab is determined to enforce its rights to intellectual property it has worked tirelessly to develop over the course of many years. It has developed a substantial patent portfolio, including a number of pending patent applications in the same family as the ‘957 patent. RegenLab remains dedicated to researching, creating, and producing superior products—and to protecting its customers from copycat manufacturers and distributors.